Form 8-K - Current report:
SEC Accession No. 0001213900-25-045643
Filing Date
2025-05-20
Accepted
2025-05-20 07:37:50
Documents
13
Period of Report
2025-05-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea024276701-8k_apimed.htm   iXBRL 8-K 25001
2 FORM OF AMENDMENT TO PROMISSORY NOTE ea024276701ex10-1_apimed.htm EX-10.1 5177
  Complete submission text file 0001213900-25-045643.txt   199027

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE apus-20250516.xsd EX-101.SCH 3017
4 XBRL LABEL FILE apus-20250516_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE apus-20250516_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT ea024276701-8k_apimed_htm.xml XML 3810
Mailing Address 2 EAST BROAD STREET 2ND FLOOR HOPEWELL NJ 08525
Business Address 2 EAST BROAD STREET 2ND FLOOR HOPEWELL NJ 08525 609-751-4485
Apimeds Pharmaceuticals US, Inc. (Filer) CIK: 0001894525 (see all company filings)

EIN.: 851099700 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42545 | Film No.: 25966171
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)